Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
Abivax
Abivax
Activities:
Research & Development
Pharmaceutical
X
LinkedIn
Trending Articles
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
How advanced technologies are unlocking the future of drug manufacturing
As the drug production landscape changes, it opens the door to pursue hybrid opportunities that push the boundaries of technological advancement in the field, reports Jon...
Andelyn Biosciences and Grace Science, LLC partner to manufacture AAV gene therapy
The partnership will seek to maximise programme efficiency, support the ongoing clinical trial and accelerate this critical therapy to patients
Teva UK and Closed Loop Medicine partner to advance personalised medicine development
SaMD platform aims to advance personalised medicine development, improve drug efficacy and patient outcomes with specific chronic conditions
Henkel facilities receive EXCiPACT certificate as suppliers of pharmaceutical excipients
The certification means Henkel meets EXCiPACT’s guidelines for good manufacturing practice (GMP) and good distribution practice (GDP)
Upcoming event
BioProcess International Europe
9-12 April 2024 | Exhibition | RAI Amsterdam
See all
Related Content
Recruitment
Abivax strengthens its management team
Regulatory
ABIVAX’s ABX464 reduces HIV reservoir in blood in second phase clinical trial
ABX464 is the first drug candidate to show statistically significant (p<0.01) reduction of the HIV viral reservoir
Research & Development
Evotec and ABIVAX collaborate to develop novel antiviral agents
Evotec and ABIVAX have announced a strategic collaboration to discover and develop novel treatments for multiple viral infectious diseases
Regulatory
First ever evidence of treatment-induced reduction in HIV reservoirs
Preliminary clinical trial results support ABX464's potential to become a key functional cure element for HIV
Manufacturing
Abivax enters into a manufacturing agreement with PCAS for ABX464
Collaboration ensures drug candidate supply for upcoming clinical trials
Research & Development
Abivax makes three new personnel changes
Including the appointment of a new Chief Medical Officer
Pharmaceutical
Abivax makes two appointments to executive management team
Karl Birthistle joins as VP of Global Regulatory Affairs, while Daniel Kenny becomes VP of Business Development
Subscribe now